Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 312 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 How to Provide Support as a Long-Distance Cancer Caregiver January 25, 2021 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Load more HOT NEWS Our nurses answer your frequently asked questions about cancer Talking About Your Sexual Orientation and Gender Identity With Your Cancer... Breast Cancer Death Rates Will Rise in Elderly EU Patients but... Ifosfamide May Be Treatment of Choice for Some People with Ewing...
